hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-15. Anything still debated is marked as such rather than presented as settled.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
It also stated that a laboratory origin for the virus was "extremely unlikely". WHO director-general Tedros Adhanom Ghebreyesus, in concert with various governments including the US and the EU, responded to the 2021 study report saying the matter still "requires further investigation". In July 2021, Zeng Yixin, Vice Health Minister of the Chinese National Health Commission, said that China would not participate in a second phase of investigation, denouncing the decision to proceed as "shocking" and "arrogant". In June 2022, a second round of investigations concluded that more investigations in the various possible pathways of emergence were necessary. In response to the WHO's June 2022 report, Chinese Foreign Ministry spokesperson Zhao Lijian called the lab leak theory "a lie concocted by anti-China forces for political purposes, which has nothing to do with science".
Humans use water for many recreational purposes, as well as for exercising and for sports. Some of these include swimming, waterskiing, boating, surfing and diving. In addition, some sports, like ice hockey and ice skating, are played on ice. Lakesides, beaches and water parks are popular places for people to go to relax and enjoy recreation. Many find the sound and appearance of flowing water to be calming, and fountains and other flowing water structures are popular decorations. Some keep fish and other flora and fauna inside aquariums or ponds for show, fun, and companionship. Humans also use water for snow sports, such as skiing, sledding, snowmobiling or snowboarding, which require the water to be at a low temperature either as ice or crystallized into snow.
== Electronic integration == Integration of microfluidic platforms and electronic components have the potential to generate micro total analysis systems (μTAS), which are devices that include and automate all essential steps for sample preparation and analysis. Paper electronics rely on functional structures like conductors to be fabricated on the surface of paper, but paper-based microfluidics rely on channels and barriers to be fabricated inside the substrate. This incompatibility led to a majority of μTAS being developed using external electrodes contacted with the paper channels. However, in 2009, screen-printed electrodes were integrated into a paper-based microfluidic device to create a biosensor for glucose, lactate, and uric acid. This first report of electronic integration for paper-based microfluidics illustrated how this can improve the design of μTAS at a low cost. Since then, a variety of electrode fabrication techniques have been developed, including screen printing, inkjet printing, metal sputter deposition, pencil drawing, laser-induced pyrolysis and external electrodes to create a network of conductive traces.
Sources: en.wikipedia.org
For services to Business and to the UK Film Industry. Catherine Anne Goodman, LVO. Artist and Educator. For services to Art. Professor Roger James Goodman. Nissan Professor of Modern Japanese Studies and Warden, St. Antony's College, University of Oxford. For services to Social Science. Gayle Jean Margaret Gorman. Lately HM Chief Inspector and Chief Executive, Education Scotland. For services to Education and Charity. Gerard Arthur Georges Grech. Founder, Tech Nation and Managing Director, Founders at the University of Cambridge. For services to the Technology Sector. The Reverend Nicholas Glyn Paul Gumbel. Lately Vicar, Holy Trinity Brompton, London. For services to the Church of England. Paul Harris. Deputy Chief Executive Officer and Operations Director, HM Courts and Tribunals Service. For Public and Voluntary Service. Martin James Hewitt, QPM. Lately Chair, National Police Chiefs Council. For services to Policing. Professor Peter Michael Hollingsworth. Director of Science and Deputy Keeper, Royal Botanic Garden, Edinburgh. For services to Botanical Science. Karl James Hoods. Chief Digital and Information Officer, Department for Science, Innovation and Technology and Department for Energy Security and Net Zero. For services to Technology and to Education. Professor Andrew Lee Hopkins, FRS, FMedSci, FRSE. Chief Executive Officer, Exscientia. For services to Science and to Innovation. Christian Edward Johnston Horner, OBE. Team Principal and Chief Executive Officer, Red Bull Racing. For services to Motor Sport. Pauline Jean Howie, OBE.
In 1994, HCFA stated that in vitro fertilization was categorized as a therapeutic procedure, not a diagnostic procedure, and therefore not covered under CLIA. As such, AAB/ABB took the position that IVF laboratory tests are covered under CLIA, while ASRM and SART took the opposing position. On September 16, 1998, the Clinical Laboratory Improvement Advisory Committee (CLIAC) made a non-binding recommendation that CLIA coverage apply to embryology laboratories and suggested the College of American Pathologists (CAP) and ASRM accreditation checklist. However, the United States Secretary of Health and Human Services Donna Shalala did not implement the recommendation prompting the AAB to sue HHS to force a decision on March 16, 1999. In response, ASRM filed an amicus brief opposing AAB's lawsuit. On March 8, 2000, the lawsuit was dismissed by Thomas F. Hogan due to lack of standing. In 1994, the American Board of Bioanalysis (ABB) created the first CLIA-approved HCLD board exam for andrologists and embryologists.
Custom peptide synthesis is the commercial production of peptides for use in biochemistry, biology, biotechnology, pharmacology and molecular medicine. Custom peptide synthesis provides synthetic peptides as valuable tools to biomedical laboratories. Synthetic oligopeptides are used extensively in research for structure-function analysis (for example to study protein-protein interfaces), for the development of binding assays, the study of receptor agonist/antagonists or as immunogens for the production of specific antibodies. Generally, peptides are synthesized by coupling the carboxyl group or C-terminus of one amino acid to the amino group or N-terminus of another using automated solid phase peptide synthesis chemistries. However, liquid phase synthesis may also be used for specific needs.
== Dosage == Paregoric is sometimes confused with laudanum because their chemical names are similar: camphorated tincture of opium (paregoric) vs. tincture of opium (laudanum). However, laudanum contains 10 milligrams of morphine per milliliter, 25 times more than paregoric. Confusion between the two drugs has led to overdose and death in patients. Thus the term "paregoric" should be used instead of "camphorated opium tincture", since the latter may be confused with laudanum.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.